In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Lanreotide | Natural peptide HGH (somatotropin) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 585 | 1,108 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 98 (98 in people) | 110 (108 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 85 · 8 active25 more mention it but do not test it | 358 · 32 active72 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Somatuline Depot says: “Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Lanreotide | HGH (somatotropin) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 11810918 | 10691 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Genotropin says: “Replacement in adults with adult-onset or childhood-onset GHD”
| Adverse eventsWhole body | 6868 | 60582 |
|---|
| Glycemic controlMetabolic and weight | 1616 | 8585 |
|---|
| LipidsMetabolic and weight | 11 | 7373 |
|---|
| Body weightMetabolic and weight | 22 | 46415 |
|---|
| Exercise and physical functionCancer | 33 | 4141 |
|---|
| Heart functionCardiovascular | 321 | 4040 |
|---|
| PharmacokineticsPharmacology | 2929 | 23320 |
|---|
| Gastrointestinal protectionGastrointestinal | 3535 | 44 |
|---|
| Protein and amino acid metabolismMetabolic and weight | 44 | 3131 |
|---|
| Receptor activity and mechanismPharmacology | 252419 | 2626 |
|---|
| Quality of lifeWhole body | 1111 | 2121 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 85 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ipsen264 participantsJun 2006 to Apr 2013
Endocrine Tumors
Novartis Pharmaceuticals198 participants19 Jul 2010 to 28 Feb 2017
Acromegaly
Ipsen128 participantsOct 2014 to 16 Feb 2017
Acromegaly
25 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 358 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S712 participantsJul 2007 to Dec 2008
Chronic Kidney Disease · End-Stage Renal Disease
EMD Serono326 participants28 May 2004 to 28 Sept 2005
HIV Infections · Lipodystrophy
Pfizer316 participantsDec 2006 to Aug 2012
Idiopathic Short Stature
72 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Lanreotide | HGH (somatotropin) |
|---|---|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in ml/min/1.73 m2 per year | −0.08 mL/min/1.73 m2 per year difference in annual eGFR decline Dose studied: 120 mg every 4 weeks2.5 yearsn = 3092018 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Quality of lifeWhole bodyCompared as: difference from placebo, in units per year | −0.03 units per year difference in quality-of-life change Dose studied: 120 mg every 4 weeks2.5 yearsn = 3092018 | No comparable result |
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in cm/year | No comparable result 10 randomized-trial results measure it in another way or another unit. | 9.78 cm/year Height velocity · somatropin at month 12 Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022 |
| Wound healingSkin and woundCompared as: difference from placebo, in p | 0.18 P P value Dose studied: 90 mgn = 1452012 | No comparable result |
| Intensive care and hospital outcomesWhole bodyCompared as: value in the arm that got the peptide, in days | 4.5 days Postoperative hospital stay, mean · lanreotide pretreatment, +/-1.6 Dose studied: 30 mg every 2 weeks, increased to weekly at week 8 if mean GH >2.5 microg/l4 monthsn = 982010 | |
| MortalityWhole bodyCompared as: value in the arm that got the peptide, in months | 9.5 months Median overall survival · lanreotide, 95% CI 4.8-14.3 Dose studied: 120 mg every 28 daysUp to 1 year or progressionn = 712019 | No comparable result 3 randomized-trial results measure it in another way or another unit. |
| Treatment adherence and retentionWhole bodyCompared as: value in the arm that got the peptide, in % | 59% Treatment completion Placebo: 86% Dose studied: 120 mg every 28 days72 weeksn = 442024 | |
| Blood pressureCardiovascularCompared as: value in the arm that got the peptide, in % | −13.6% change in baseline HVPG · lanreotide SR 30 mg weekly Dose studied: 30 mg once weekly3 weeksn = 242003 | No comparable result 1 randomized-trial result measure it in another way or another unit. |
| Gastrointestinal protectionGastrointestinalCompared as: difference from placebo, in % | −6.9% LS mean difference in percentage of days with SC octreotide rescue Dose studied: 120 mg every 4 weeks16 weeksn = 642018 | |
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in % | −2.9% Liver volume change Placebo: 1.6% Dose studied: 120 mg every 28 days24 weeksn = 542009 | No randomized trial result 3 results from other study designs. |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in ng.min/l | 1844.3 ng.min/L AUC extrapolated to infinity · 100 microg/h lanreotide infusion Dose studied: 100 microg/h infusion for 8 hours versus 800-microg bolusn = 122004 | |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 11.1% Hypoglycemia Placebo-treated participants: 1.4% Dose studied: 120 mg monthlythree yearsn = 1442026 | No comparable result 16 randomized-trial results measure it in another way or another unit. |
−0.08 mL/min/1.73 m2 per year
difference in annual eGFR decline
Dose studied: 120 mg every 4 weeks2.5 yearsn = 3092018
No comparable result
2 randomized-trial results measure it in another way or another unit.
4 randomized-trial results measure it in another way or another unit.
3 randomized-trial results measure it in another way or another unit.
No comparable result 3 randomized-trial results measure it in another way or another unit. |
No comparable result 2 randomized-trial results measure it in another way or another unit. |
No randomized trial result 4 results from other study designs. |
No randomized trial result
23 results from other study designs.
−0.03 units per year
difference in quality-of-life change
Dose studied: 120 mg every 4 weeks2.5 yearsn = 3092018
No comparable result
4 randomized-trial results measure it in another way or another unit.
No comparable result
10 randomized-trial results measure it in another way or another unit.
9.78 cm/year
Height velocity · somatropin at month 12
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022
0.18 P
P value
Dose studied: 90 mgn = 1452012
No comparable result
3 randomized-trial results measure it in another way or another unit.
4.5 days
Postoperative hospital stay, mean · lanreotide pretreatment, +/-1.6
Dose studied: 30 mg every 2 weeks, increased to weekly at week 8 if mean GH >2.5 microg/l4 monthsn = 982010
No comparable result
3 randomized-trial results measure it in another way or another unit.
9.5 months
Median overall survival · lanreotide, 95% CI 4.8-14.3
Dose studied: 120 mg every 28 daysUp to 1 year or progressionn = 712019
No comparable result
3 randomized-trial results measure it in another way or another unit.
59%
Treatment completion
Placebo: 86%
Dose studied: 120 mg every 28 days72 weeksn = 442024
No comparable result
2 randomized-trial results measure it in another way or another unit.
−13.6%
change in baseline HVPG · lanreotide SR 30 mg weekly
Dose studied: 30 mg once weekly3 weeksn = 242003
No comparable result
1 randomized-trial result measure it in another way or another unit.
−6.9%
LS mean difference in percentage of days with SC octreotide rescue
Dose studied: 120 mg every 4 weeks16 weeksn = 642018
No randomized trial result
4 results from other study designs.
−2.9%
Liver volume change
Placebo: 1.6%
Dose studied: 120 mg every 28 days24 weeksn = 542009
No randomized trial result
3 results from other study designs.
1844.3 ng.min/L
AUC extrapolated to infinity · 100 microg/h lanreotide infusion
Dose studied: 100 microg/h infusion for 8 hours versus 800-microg bolusn = 122004
No randomized trial result
23 results from other study designs.
11.1%
Hypoglycemia
Placebo-treated participants: 1.4%
Dose studied: 120 mg monthlythree yearsn = 1442026
No comparable result
16 randomized-trial results measure it in another way or another unit.